Immediate and Delayed Memory Performance in Schizophrenia Spectrum Patients: Use of Matched Tasks

Calev, Avraham

doi:10.1159/000049288

Cited by 2 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Delayed memory is more impaired than immediate recall in schizophrenia (Calev, 2001;Dougherty et al, 1998). Although ceiling effects limits our ability to detect performance changes, Brd1 +/À mice did not differ from WT mice when there was no delay between information and choice runs but where significantly impaired when a delay of 90 s was introduced.…”

Section: Discussionmentioning

confidence: 83%

Mice heterozygous for an inactivated allele of the schizophrenia associated Brd1 gene display selective cognitive deficits with translational relevance to schizophrenia

Qvist

Rajkumar

Redrobe

et al. 2017

Neurobiology of Learning and Memory

View full text Add to dashboard Cite

Schizophrenia is a debilitating brain disorder characterized by disturbances of emotion, perception and cognition. Cognitive impairments predict functional outcome in schizophrenia and are detectable even in the prodromal stage of the disorder. However, our understanding of the underlying neurobiology is limited and procognitive treatments remain elusive. We recently demonstrated that mice heterozygous for an inactivated allele of the schizophrenia-associated Brd1 gene (Brd1 mice) display behaviors reminiscent of schizophrenia, including impaired social cognition and long-term memory. Here, we further characterize performance of these mice by following the preclinical guidelines recommended by the 'Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS)' and 'Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia (CNTRICS)' initiatives to maximize translational value. Brd1 mice exhibit relational encoding deficits, compromised working and long term memory, as well as impaired executive cognitive functioning with cognitive behaviors relying on medial prefrontal cortex being particularly affected. Akin to patients with schizophrenia, the cognitive deficits displayed by Brd1 mice are not global, but selective. Our results underline the value of Brd1 mice as a promising tool for studying the neurobiology of cognitive deficits in schizophrenia.

show abstract

Section: Discussionmentioning

confidence: 83%

Mice heterozygous for an inactivated allele of the schizophrenia associated Brd1 gene display selective cognitive deficits with translational relevance to schizophrenia

Qvist

Rajkumar

Redrobe

et al. 2017

Neurobiology of Learning and Memory

View full text Add to dashboard Cite

show abstract

“…Previous studies have consistently demonstrated significant impairments in immediate and delayed memory in both SZ and BD II [ 41 – 44 ]. In this study, we conducted a correlation analysis between RBANS immediate and delayed memory scores and clinical improvements (PANSS scores for SZ and HAMD scores for BD II).…”

Section: Discussionmentioning

confidence: 99%

Comparison of cognitive performance in first-episode drug-naïve schizophrenia, bipolar II disorder, and major depressive disorder patients after treatment

Tang,

Huang,

Tan

et al. 2024

BMC Psychiatry

View full text Add to dashboard Cite

Background Cognitive impairment is a recognized fundamental deficit in individuals diagnosed with schizophrenia (SZ), bipolar II disorder (BD II), and major depressive disorder (MDD), among other psychiatric disorders. However, limited research has compared cognitive function among first-episode drug-naïve individuals with SZ, BD II, or MDD. Methods This study aimed to address this gap by assessing the cognitive performance of 235 participants (40 healthy controls, 58 SZ patients, 72 BD II patients, and 65 MDD patients) using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) before and after 12 weeks of treatment in SZ, BD II, and MDD patients. To clarify, the healthy controls only underwent RBANS testing at baseline, whereas the patient groups were assessed before and after treatment. The severity of symptoms in SZ patients was measured using the Positive and Negative Syndrome Scale (PANSS), and depression in BD II and MDD patients was assessed using the Hamilton Depression Scale-24 items (HAMD-24 items). Results Two hundred participants completed the 12-week treatment period, with 35 participants dropping out due to various reasons. This group included 49 SZ patients, 58 BD II patients, and 53 MDD patients. Among SZ patients, significant improvements in immediate and delayed memory were observed after 12 weeks of treatment compared to their initial scores. Similarly, BD II patients showed significant improvement in immediate and delayed memory following treatment. However, there were no significant differences in RBANS scores for MDD patients after 12 weeks of treatment. Conclusions In conclusion, the findings of this study suggest that individuals with BD II and SZ may share similar deficits in cognitive domains. It is important to note that standardized clinical treatment may have varying degrees of effectiveness in improving cognitive function in patients with BD II and SZ, which could potentially alleviate cognitive dysfunction.

show abstract

Immediate and Delayed Memory Performance in Schizophrenia Spectrum Patients: Use of Matched Tasks

Cited by 2 publications

References 32 publications

Mice heterozygous for an inactivated allele of the schizophrenia associated Brd1 gene display selective cognitive deficits with translational relevance to schizophrenia

Mice heterozygous for an inactivated allele of the schizophrenia associated Brd1 gene display selective cognitive deficits with translational relevance to schizophrenia

Comparison of cognitive performance in first-episode drug-naïve schizophrenia, bipolar II disorder, and major depressive disorder patients after treatment

Contact Info

Product

Resources

About